Yiwu Dang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yiwu Dang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Yu-Long Deng
Research Department, Affiliated Cancer Hospital, Guangxi Medical University, 530021 Nanning, Guangxi, China
2 shared publications - Yuxing Tang
Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China
2 shared publications - Beibei Huang
Research Department, Affiliated Cancer Hospital, Guangxi Medical University, 530021 Nanning, Guangxi, China
1 shared publication - Dan-Dan Xiong
Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
1 shared publication - Gang Chen
Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China
1 shared publication - Hongbo Mo
Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China
1 shared publication
Latest Publications
- Open Access
- 18 August 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (8)
Multimodal Analysis Reveals Aberrant Expression of SUMO2 and Its Significant Association With Key Mechanisms of Metabolic Pathways in Hepatocellular Carcinoma
Background:Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. However, the role of small ubiquitin-like modifier 2 (SUMO2), a core member of the small ubiquitin-like modifier (SUMO) family, regarding its expression patterns and metabolism-related functions in HCC remains inadequately understood.Methods:A multidimensional analytical framework was applied, integrating immunohistochemistry (153 HCC vs. 21 non-HCC samples), proteomics (159 paired samples), bulk transcriptomics (3240 HCC vs. 2267 non-HCC samples), single-cell RNA sequencing (RNA-seq) (10 HCC vs. 8 non-HCC samples), spatial transcriptomics, and external CRISPR/Cas9 functional genomics data. Systematic analyses included standardized mean difference (SMD), pathway enrichment, pseudotime trajectory inference, in silico knockout, cell–cell communication, metabolic flux scoring, immune infiltration, clinical correlation, drug sensitivity prediction, and molecular docking.Results:At the protein level, immunohistochemistry (nuclear positivity) and external proteomic data collectively demonstrated consistent SUMO2 overexpression in HCC. Consistent upregulation was also observed at the mRNA level across large-scale cohorts. Single-cell RNA-seq and spatial transcriptomics localized SUMO2 enrichment to malignant hepatocytes and tumor-dominant regions. CRISPR-mediated SUMO2 knockout suppressed proliferation in multiple HCC cell lines. Mechanistically, high SUMO2 expression was significantly associated with metabolic reprogramming involving glycolysis/gluconeogenesis, pyruvate metabolism, and the tricarboxylic acid cycle. SUMO2-high malignant hepatocyte subpopulations exhibited enhanced activity of the macrophage migration inhibitory factor signaling axis and enhanced iron-sensor interactions. Further, the immune infiltration analysis revealed a negative correlation between SUMO2 expression and M1 macrophages and a positive correlation between follicular helper T cells and regulatory T cells. Clinically, elevated SUMO2 levels were found to be associated with adverse prognostic features. Furthermore, high SUMO2 expression was associated with increased sensitivity to dasatinib, and molecular docking simulations predicted potential binding between SUMO2 and dasatinib, with a Vina score of −8.5 kcal/mol.Conclusions:SUMO2 is aberrantly expressed at the protein, mRNA, single-cell, and spatial transcriptomic levels in HCC and is significantly associated with metabolic reprogramming and altered migration inhibitory factor (MIF)-mediated intercellular communication, suggesting its potential as a novel biomarker for diagnosis and treatment.
- 18 August 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (8)
Open AccessMultimodal Analysis Reveals Aberrant Expression of SUMO2 and Its Significant Association With Key Mechanisms of Metabolic Pathways in Hepatocellular Carcinoma
Background:Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. However, the role of small ubiquitin-like modifier 2 (SUMO2), a core member of the small ubiquitin-like modifier (SUMO) family, regarding its expression patterns and metabolism-related functions in HCC remains inadequately understood.Methods:A multidimensional analytical framework was applied, integrating immunohistochemistry (153 HCC vs. 21 non-HCC samples), proteomics (159 paired samples), bulk transcriptomics (3240 HCC vs. 2267 non-HCC samples), single-cell RNA sequencing (RNA-seq) (10 HCC vs. 8 non-HCC samples), spatial transcriptomics, and external CRISPR/Cas9 functional genomics data. Systematic analyses included standardized mean difference (SMD), pathway enrichment, pseudotime trajectory inference, in silico knockout, cell–cell communication, metabolic flux scoring, immune infiltration, clinical correlation, drug sensitivity prediction, and molecular docking.Results:At the protein level, immunohistochemistry (nuclear positivity) and external proteomic data collectively demonstrated consistent SUMO2 overexpression in HCC. Consistent upregulation was also observed at the mRNA level across large-scale cohorts. Single-cell RNA-seq and spatial transcriptomics localized SUMO2 enrichment to malignant hepatocytes and tumor-dominant regions. CRISPR-mediated SUMO2 knockout suppressed proliferation in multiple HCC cell lines. Mechanistically, high SUMO2 expression was significantly associated with metabolic reprogramming involving glycolysis/gluconeogenesis, pyruvate metabolism, and the tricarboxylic acid cycle. SUMO2-high malignant hepatocyte subpopulations exhibited enhanced activity of the macrophage migration inhibitory factor signaling axis and enhanced iron-sensor interactions. Further, the immune infiltration analysis revealed a negative correlation between SUMO2 expression and M1 macrophages and a positive correlation between follicular helper T cells and regulatory T cells. Clinically, elevated SUMO2 levels were found to be associated with adverse prognostic features. Furthermore, high SUMO2 expression was associated with increased sensitivity to dasatinib, and molecular docking simulations predicted potential binding between SUMO2 and dasatinib, with a Vina score of −8.5 kcal/mol.Conclusions:SUMO2 is aberrantly expressed at the protein, mRNA, single-cell, and spatial transcriptomic levels in HCC and is significantly associated with metabolic reprogramming and altered migration inhibitory factor (MIF)-mediated intercellular communication, suggesting its potential as a novel biomarker for diagnosis and treatment.
- Open Access
- 21 April 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (4) , 49215
Multi-Dimensional Data Integration Reveals the Molecular Mechanism of Metabolic Reprogramming Associated With Low Asparaginase Expression in Hepatocellular Carcinoma
Background: To investigate the impact of low expression of asparaginase (ASPG) in hepatocellular carcinoma (HCC) on tumor metabolic reprogramming, tumor microenvironment interactions, and drug sensitivity, and to assess the potential of ASPG as a tumor suppressor gene through multi-dimensional functional mechanisms. Methods: Thus, ASPG expression in HCC was systemically evaluated by integrating global multi-center mRNA datasets, including RNA-seq and microarray data from 3967 HCCs and 2645 non-HCC samples, single-cell RNA sequencing (scRNA-seq) data from 10 HCCs and 8 adjacent normal tissues, spatial transcriptomics (STs), and internal immunohistochemistry data from 301 HCCs and matched adjacent liver tissues. A CRISPR-mediated gene knockout model was employed to examine the effects of ASPG deletion on HCC cell proliferation. ASPG-associated regulatory pathways were analyzed using Gene Set Enrichment Analysis (GSEA), GeneMANIA, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment. Changes in ligand–receptor interactions between low-expression ASPG (ASPG-low) and the tumor microenvironment were examined using CellChat, based on scRNA-seq data. Single-cell metabolism (scmetabolism) and single-cell flux estimation analysis (scFEA) were applied to infer metabolic activity and metabolite conversion pathways under ASPG-low conditions. Finally, correlations between ASPG expression and the IC50 values of anticancer drugs were assessed using OncoPredict. Results: Multi-dimensional analyses consistently showed that both ASPG mRNA and protein levels were significantly downregulated in HCC. CRISPR-mediated ASPG knockout was associated with significantly increased cell proliferation. Mechanistically, HCC cells with low ASPG expression were enriched in pathways related to alanine, aspartate, and glutamate metabolism, as well as amino acid biosynthesis, gluconeogenesis, and lipid metabolism. Cell–cell communication analysis revealed strong interactions between ASPG-low malignant hepatocytes and myeloid cells, with significant activation of the MIF–(CD74+CXCR4) and MIF–(CD74+CD44) signaling axes. Metabolic analysis demonstrated that the ASPG-low state was associated with alanine, aspartate, and glutamate metabolism, as well as the citric acid (TCA) cycle, thereby regulating the conversion of the aspartate–asparagine and glutamate–2OG metabolites. ASPG-low HCC was associated with resistance to drugs such as cisplatin, oxaliplatin, and gemcitabine, but increased sensitivity to lapatinib and paclitaxel. Conclusion: Low ASPG expression in HCC may drive aspartate metabolism and reprogramming of the TCA cycle, thereby influencing sensitivity to drug treatment.
- 21 April 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (4) , 49215
Open AccessMulti-Dimensional Data Integration Reveals the Molecular Mechanism of Metabolic Reprogramming Associated With Low Asparaginase Expression in Hepatocellular Carcinoma
Background: To investigate the impact of low expression of asparaginase (ASPG) in hepatocellular carcinoma (HCC) on tumor metabolic reprogramming, tumor microenvironment interactions, and drug sensitivity, and to assess the potential of ASPG as a tumor suppressor gene through multi-dimensional functional mechanisms. Methods: Thus, ASPG expression in HCC was systemically evaluated by integrating global multi-center mRNA datasets, including RNA-seq and microarray data from 3967 HCCs and 2645 non-HCC samples, single-cell RNA sequencing (scRNA-seq) data from 10 HCCs and 8 adjacent normal tissues, spatial transcriptomics (STs), and internal immunohistochemistry data from 301 HCCs and matched adjacent liver tissues. A CRISPR-mediated gene knockout model was employed to examine the effects of ASPG deletion on HCC cell proliferation. ASPG-associated regulatory pathways were analyzed using Gene Set Enrichment Analysis (GSEA), GeneMANIA, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment. Changes in ligand–receptor interactions between low-expression ASPG (ASPG-low) and the tumor microenvironment were examined using CellChat, based on scRNA-seq data. Single-cell metabolism (scmetabolism) and single-cell flux estimation analysis (scFEA) were applied to infer metabolic activity and metabolite conversion pathways under ASPG-low conditions. Finally, correlations between ASPG expression and the IC50 values of anticancer drugs were assessed using OncoPredict. Results: Multi-dimensional analyses consistently showed that both ASPG mRNA and protein levels were significantly downregulated in HCC. CRISPR-mediated ASPG knockout was associated with significantly increased cell proliferation. Mechanistically, HCC cells with low ASPG expression were enriched in pathways related to alanine, aspartate, and glutamate metabolism, as well as amino acid biosynthesis, gluconeogenesis, and lipid metabolism. Cell–cell communication analysis revealed strong interactions between ASPG-low malignant hepatocytes and myeloid cells, with significant activation of the MIF–(CD74+CXCR4) and MIF–(CD74+CD44) signaling axes. Metabolic analysis demonstrated that the ASPG-low state was associated with alanine, aspartate, and glutamate metabolism, as well as the citric acid (TCA) cycle, thereby regulating the conversion of the aspartate–asparagine and glutamate–2OG metabolites. ASPG-low HCC was associated with resistance to drugs such as cisplatin, oxaliplatin, and gemcitabine, but increased sensitivity to lapatinib and paclitaxel. Conclusion: Low ASPG expression in HCC may drive aspartate metabolism and reprogramming of the TCA cycle, thereby influencing sensitivity to drug treatment.